3 results about "Release modulator" patented technology

The invention relates to the technical field of drug sustained-release microspheres, and particularly provides a dalotamide sustained-release microsphere which is of a structure composed of an inner layer and an outer layer, and the inner layer is coated with the outer layer; the inner layer is prepared from the following raw material components: first PLGA and dalotamide; the outer layer is prepared from the following raw material components: second PLGA, dalotamide dispersed particles and a release regulator; the dalotamide dispersed particles are prepared from the dalotamide and Soluplus; the release regulator is selected from a hydrophilic substance and / or a pore-foaming agent. According to the microspheres disclosed by the invention, the programmed release effect of'early-stage quick release-medium-stage stable release-long-term slow release 'of the dalotamide can be realized, and the stability of the dalotamide is good.

The invention discloses a lyotropic liquid crystal long-acting injection as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The preparation consists of a raw material medicine, a lipid material, an organic solvent and a release regulator, and hexagonal phase liquid crystal gel can be spontaneously formed after injection so as to realize long-acting slow release. The preparation can be prepared by stirring and mixing at room temperature, and has the advantage of simple and convenient preparation process. Experiments show that the effective blood concentration in the body can be maintained for more than 14 days after single hypodermic injection, the half-life period of the medicine is prolonged to 187 hours from about 66 hours of oral administration, and the burst release phenomenon is avoided. The invention effectively solves the clinical pain points of frequent administration, large blood concentration fluctuation, poor patient compliance and the like of the existing oral preparation of the hydrobromic acid vortioxetine.

This invention belongs to the field of pharmaceutical technology, specifically relating to an injectable sustained-release composition, its preparation method, and its application. Through extensive research, this invention unexpectedly discovered that adding specific release modifiers can significantly slow down the early release rate of drugs. Furthermore, there is a synergistic effect between specific release modifiers and specific structure modifiers, which can effectively improve the sustained-release performance of the composition and significantly reduce the coefficient of variation among individual animals.